Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2024-08-25
Target enrollment:
Participant gender:
Summary
This research study is investigating a drug as a possible treatment for metastatic renal cell
carcinoma. The intervention involved in this study is TAK-228.
Phase:
Phase 2
Details
Lead Sponsor:
Bradley A. McGregor Dana-Farber Cancer Institute
Collaborators:
Millennium Pharmaceuticals, Inc. Millennium: The Takeda Oncology Company